Mary Wilson
Well-known member
Blood Transfus 2021; 19: 281-3 DOI 10.2450/2021.0117-21 © SIMTIPRO Srl
Paolo Gresele1, Marco Marietta2, Walter Ageno3, Rossella Marcucci4,Laura Contino5, Marco P. Donadini6, Laura Russo7, Giovanni L. Tiscia8,Gualtiero Palareti9, Armando Tripodi10, Pier Mannuccio Mannucci10,Valerio De Stefano11
ChAdOx1 nCOV-19 (Vaxzevria) is a vaccine against SARS-CoV-2 infection (COVID-19) developed by Oxford University and AstraZeneca that uses a replication-de cient chimpanzee adenoviral vector (ChAdOx1) containing the SARS-CoV-2 structural surface glycoprotein antigen (spike protein; nCoV-19) gene1.
Over the last few weeks, there have been several reports of thromboembolic events in subjects who had been administered Vaxzevria in the previous weeks. is led several European countries to decide to suspend its administration or, more recently, to limit it to subjects over 60 years of age2,3.
While the incidence of venous thromboembolism (VTE) at usual sites in vaccinated subjects has not exceeded that in the non-vaccinated population4,5, a rare and particulartype of event has been described following vaccination. is is characterised by cerebral and/or splanchnic vein thrombosis, often associated with multiple thromboses, with thrombocytopenia and bleeding, and sometimes disseminated intravascular coagulation (DIC), occurring in otherwise healthy subjects. is syndrome was mainly observed in females under 55 years of age, and the events occurred between 4 and 16 days af ter receiving the Vaxzevria vaccine, with a high fatality rate. It is known that it may be extremely dif cult to prove that an adverse event following immunisation is actually caused by the vaccine itself when its occurrence is extremely rare6. However, the described clinical picture requires attention and it is emerging as a likely, although very rare, complication of vaccination with Vaxzevria7.
...
http://www.bloodtransfusion.it/arti..._medium=&utm_term=&utm_content=&utm_campaign=
Paolo Gresele1, Marco Marietta2, Walter Ageno3, Rossella Marcucci4,Laura Contino5, Marco P. Donadini6, Laura Russo7, Giovanni L. Tiscia8,Gualtiero Palareti9, Armando Tripodi10, Pier Mannuccio Mannucci10,Valerio De Stefano11
ChAdOx1 nCOV-19 (Vaxzevria) is a vaccine against SARS-CoV-2 infection (COVID-19) developed by Oxford University and AstraZeneca that uses a replication-de cient chimpanzee adenoviral vector (ChAdOx1) containing the SARS-CoV-2 structural surface glycoprotein antigen (spike protein; nCoV-19) gene1.
Over the last few weeks, there have been several reports of thromboembolic events in subjects who had been administered Vaxzevria in the previous weeks. is led several European countries to decide to suspend its administration or, more recently, to limit it to subjects over 60 years of age2,3.
While the incidence of venous thromboembolism (VTE) at usual sites in vaccinated subjects has not exceeded that in the non-vaccinated population4,5, a rare and particulartype of event has been described following vaccination. is is characterised by cerebral and/or splanchnic vein thrombosis, often associated with multiple thromboses, with thrombocytopenia and bleeding, and sometimes disseminated intravascular coagulation (DIC), occurring in otherwise healthy subjects. is syndrome was mainly observed in females under 55 years of age, and the events occurred between 4 and 16 days af ter receiving the Vaxzevria vaccine, with a high fatality rate. It is known that it may be extremely dif cult to prove that an adverse event following immunisation is actually caused by the vaccine itself when its occurrence is extremely rare6. However, the described clinical picture requires attention and it is emerging as a likely, although very rare, complication of vaccination with Vaxzevria7.
...
http://www.bloodtransfusion.it/arti..._medium=&utm_term=&utm_content=&utm_campaign=